Progression Free Survival Increases regardless of PDL-1 Expressions
Progression Free Survival Increases regardless of PDL-1 Expressions
Foreword on Article by Steve Holmes
Better Survival outcomes for those without PDL-1 expression!
This is one of those articles that I like to keep an eye on. So many CC patients miss the Imunno options due to lack of PDL-1 Expression.
I try to widen my vision just enough to pull together opportunities that are not quite options in our CC environment yet, but could be. Some extra research and understanding that keeps me plugged in to what could be !
Hope this info helps
Regards Steve
The Cholangio Crusader + Immuno Warrior
Yes I made that title tagline up, but it sounds catchy and real!
I have to keep the smile on my dial any way I can and then share some.
www.steveholmes.net.au
Starving Tumors of Important Amino Acid May Extend Survival in Pancreatic Cancer
By Ariela Katz
Published: Monday, Oct 08, 2018
This is published by
Click here for Full Article
The combination of avelumab (Bavencio) and axitinib (Inlyta) doubled objective response rates (ORRs) and significantly improved progression-free survival (PFS) compared with sunitinib (Sutent) in patients with treatment-naïve advanced renal cell carcinoma (RCC) regardless of PD-L1 expression, according to findings from the phase III JAVELIN Renal 101 trial presented at the 2018 ESMO Congress.
“This trial demonstrated longer progression-free survival and higher objective response rates for avelumab plus axitinib, a checkpoint inhibitor plus a VEGF inhibitor regimen, compared with sunitinib as first-line treatment for advanced RCC,” said lead study author Robert J. Motzer, a medical oncologist at Memorial Sloan Kettering Cancer Center. “The results support this being a new standard of care for first-line treatment of [patients with] advanced RCC.”
Continue reading via drop downs [+]